Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

An update from Quantum Biopharma ( (TSE:QNTM)) is now available. On December 23, 2025, Quantum BioPharma announced it has completed oral dosing in its 180-day repeated-dose oral toxicity and ...

Grade Purity, Third-Party Testing, and Mitochondrial Support Claims Are Reshaping Consumer Evaluation Standards for Methylene ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen ...

Attorney General Pam Bondi shared and then deleted a graph showing a steep drop in drug overdose deaths after she was busted trying to give the Trump administration credit for progress made under Joe ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, ...

Mounjaro’s typical starting dosage is 2.5 milligrams (mg) once per week for 4 weeks, after which your doctor may increase the dose to 5 mg per week if needed to manage blood sugar levels. The ...

Over-the-counter (OTC) fever reducers, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, are some of the most common medications. Both can help lower fever and ...

An accidental mixed-drug toxicity caused the death of a 45-year-old former Livingston man who went missing last month south of Butte, coroner Lee LaBreche said.

About Bright Minds Biosciences Inc. Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P.